Snowden Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Snowden Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,209	Closed	-$272K	–	1239
2024 Q4	$272K	Sell	2,209 -242	-10%	-$28.5K	0.01%	1031
2024 Q3	$273K	Buy	+2,451	New	+$269K	0.01%	1042
2024 Q2	–	Sell	-1,666	Closed	-$201K	–	1207
2024 Q1	$201K	Buy	+1,666	New	+$204K	0.01%	1131
2023 Q1	–	Sell	-1,353	Closed	-$216K	–	1173
2022 Q4	$216K	Buy	+1,353	New	+$198K	0.01%	1037
2022 Q1	–	Sell	-29	Closed	-$3K	–	1562
2021 Q4	$3K	Buy	+29	New	+$3.81K	﹤0.01%	1808

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Snowden Capital Advisors's JAZZ Position: Q1 2025 in Review

Snowden Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 2,209 shares — an estimated $272K sold.

Snowden Capital Advisors first reported a position in JAZZ in Q4 2021 and held it in 5 quarters. The position peaked at $273K in Q3 2024. 551 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

Snowden Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Snowden Capital Advisors sold 2,209 Jazz Pharmaceuticals shares in Q1 2025, an estimated $272K.
Snowden Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 5 quarters.
Snowden Capital Advisors's Jazz Pharmaceuticals position peaked at $273K in Q3 2024.
551 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Snowden Capital Advisors's 13F filing for Q1 2025, filed 14 May 2025.